ClinicalTrials.gg
CompletedNCT04794491Updated Jan 9, 2024Results posted

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

A Phase 4 interventional study of JZP-258 in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 28 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Jazz Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
11th of 15
62 · median 120
Started
2021
with 1 other
Phase 4
3 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 12th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant must be 18 to 80 years of age (inclusive), at the time of signing the . Type of Participant and Disease Characteristics
  2. Participants who have a primary diagnosis of Type 1 or Type 2 narcolepsy that meets ICSD-3 criteria or criteria (Ruoff and Rye 2016), and are being currently treated with Xyrem, with or without additional anticataplectics or stimulants.
  3. Participants who have been taking Xyrem (with or without additional anticataplectics or stimulants eg, TCA, SNRI, SSRI, atomoxetine) in a stable dose and regimen for at least two months prior to screening, with evidence of clinical improvement on their current regimen, per the investigator's judgement. Only Xyrem will be substituted with XYWAV, with dose and regimen of any concomitant anticataplectics or stimulants remaining unchanged throughout the study.

    Sex and /Barrier Requirements

  4. Participant is male or female

    • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

      • Is a woman of non- (WONCBP) as defined in Appendix 3 OR
      • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year), preferably with low user dependency, as described in Appendix 3, during the study Intervention period and for at least 7 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention.
    • A WOCBP must have a negative highly sensitive pregnancy test (serum) during screening.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

    Informed Consent

  5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Have a diagnosis of narcolepsy, secondary to another medical condition (eg, central nervous system injury or lesion)
  2. Are currently prescribed a Xyrem regimen exceeding a dose of 9 grams nightly, or any single dose in excess of 6 grams.
  3. Have been diagnosed with restless leg syndrome (RLS) requiring treatment other than iron supplements
  4. Exhibit succinic semi-aldehyde dehydrogenase deficiency (SSADH)
  5. Have uncontrolled hypothyroidism
  6. Have a history of seizures, excluding early childhood non-pathological febrile seizures
  7. Have a history of head trauma associated with loss of consciousness in the past 5 years, or if the event occurred more than 5 years prior to screening and the participant experiences sequelae due to the event
  8. Show evidence of untreated or inadequately treated sleep-disordered breathing including:

    1. Presence of and untreated obstructive or central sleep apnea (as determined by the investigator or documented previously); or one of the following:
    2. Apnea index (AI) >10 if on Obstructive Sleep Apnea (OSA) treatment or untreated, or
    3. Clinically significant hypoventilation, or
    4. Noncompliance with primary OSA therapy Note: "Non-compliance" is defined as positive airway pressure use of \<4 hours per night on \<70% of nights (\<5 of 7 nights/week) per historical report (with investigator concurrence) of use of an oral appliance on \<70% of nights (≥5 of 7 nights/week), or receipt of an effective surgical intervention for OSA symptoms.
  9. Experience parasomnias (eg, sleep walking, REM Sleep Behavior Disorder, etc.) considered by the investigator to negatively impact the conduct of the study. Parasomnia events associated with physical injury to the participant (or others) shall be discussed with the sponsor Medical Monitor.
  10. Meet criteria for current major depression based on clinical interview
  11. Have any clinically relevant medical, behavioral, or psychiatric disorder (other than narcolepsy) that is associated with excessive sleepiness
  12. Have a history or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to criteria
  13. Have a history or presence of any unstable or clinically significant medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or history or presence of another neurological disorder or surgical history that might affect the participant's safety and/or interfere with the conduct of the study, in the opinion of the investigator
  14. Display relevant suicidality as indicated by Columbia Suicide Severity Rating Scale (C-SSRS) evaluation at screening
  15. Display moderate to severe depression as indicated by the Participant Health Questionnaire - 9 (PHQ-9) at screening
  16. Are a female participant who is pregnant or breastfeeding

    Prior/Concomitant Therapy

  17. Have undergone treatment with any prohibited central nervous system (CNS) agents, including but not limited to benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, phenytoin, ethosuximide, or MCT inhibitors, eg, diclofenac, valproate, ibuprofen, within 2 weeks prior to enrollment. Discontinuation for the purpose of study enrollment is permitted only if considered safe by the investigator and approved by the Medical Monitors.

    Prior/Concurrent Clinical Study Experience

  18. Received any other drug within 30 days or five half-lives (whichever is longer) prior to screening, or plan to use an investigational drug (other than the study intervention) during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Open-Label Conversion and Treatment Optimization

    Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.

    Drug: JZP-258

Interventions

  • Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g

    Also known as: XYWAV

06

What researchers measure

Primary outcomes

  1. Change in Weekly Rate of Cataplexy Attacks

    Mean weekly rate of cataplexy attack = (total number of cataplexy attacks reported during the period/number of days during the period where a diary was completed) x 7.

    Time frame: Baseline to Week 8

Other outcomes

  1. Change in the Nausea Visual Analog Scale (NVAS)

    Tolerability associated with Xyrem and XYWAV was measured based on an NVAS assessment administered electronically. NVAS was captured daily during the last 7 days of the Baseline (Xyrem-stable dose and regimen) period and the last 7 days of the Intervention period (on XYWAV) prior to the ET visit or prior to the E/D visit, if possible. For participants with at least one day of NVAS data, the NVAS for that week was the average daily score from days with non-missing data within the week, then multiplied by 7. The NVAS ranges 0-100 mm, with higher scores representing more severe/intense nausea.

    Time frame: Baseline to Week 8

  2. Number of Participants With Patient Global Impression of Change (PGIc) Values

    The PGIc is a 7-point Likert-type rating based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). PGIc values were measured at the ET or E/D, as applicable.

    Time frame: Week 8

  3. Change in Epworth Sleepiness Scale (ESS)

    The ESS questionnaire included a set of 8 questions regarding how likely the participant would be to doze off or fall asleep in different situations. The ESS measures EDS or average sleep propensity in daily life. Responses range from 0 = would never doze (better outcome) to 3 = high chance of dozing (worse outcome). Changes in ESS scores were assessed between the Baseline period and ET or E/D, as applicable

    Time frame: Baseline to Week 8

  4. Time to Achieve Optimized Dose and Regimen

    Defined as the time from the first dose and regimen to the optimized dose and regimen of XYWAV, where the optimized dose and regimen indicates the final dose and regimen that remains unchanged throughout the remainder of the Intervention period.

    Time frame: Baseline to Week 8

  5. Number of Changes From the First Dose and Regimen to Optimized Dose and Regimen

    The amount of times the dose and regimen were changed before an optimized dose and regimen were achieved.

    Time frame: Baseline to Week 8

  6. Number of Participants Dosing Fasted Versus Dosing Without Consideration of Food

    Once the participant reached an optimized dose and regimen, the investigator could decide to instruct the participant to dose without regard to food.

    Time frame: Baseline to Week 8

  7. Duration of Time Between the Last Meal Relative to Dosing

    The difference between the time of day that participants ate their last meal and the time of day participants take their first dose.

    Time frame: Baseline to Week 8

  8. Characterization of Meals Relative to Dosing

    Types of meals consumed before dosing.

    Time frame: Baseline to Week 8

07

Results

Posted Jan 9, 2024

Participant flow

A total of 62 participants were enrolled in trial sites across the United States.

Participant flow — Overall Study
MilestoneOverall
Started62
Baseline period62
Intervention (xywav) period60
Safety follow-up period59
Completed54
Not completed8
Withdrew: Adverse event1
Withdrew: Alcohol or urine drug screen result is positive4
Withdrew: Noncompliance with study intervention1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryChange in Weekly Rate of Cataplexy Attacks

Mean weekly rate of cataplexy attack = (total number of cataplexy attacks reported during the period/number of days during the period where a diary was completed) x 7.

Time frame:
Baseline to Week 8
Reported as:
Mean · cataplexy attacks per week
Change in Weekly Rate of Cataplexy Attacks
cataplexy attacks per weekOverall
Change in Weekly Rate of Cataplexy Attacks0.98 ± 4.1222
Other pre-specifiedChange in the Nausea Visual Analog Scale (NVAS)

Tolerability associated with Xyrem and XYWAV was measured based on an NVAS assessment administered electronically. NVAS was captured daily during the last 7 days of the Baseline (Xyrem-stable dose and regimen) period and the last 7 days of the Intervention period (on XYWAV) prior to the ET visit or prior to the E/D visit, if possible. For participants with at least one day of NVAS data, the NVAS for that week was the average daily score from days with non-missing data within the week, then multiplied by 7. The NVAS ranges 0-100 mm, with higher scores representing more severe/intense nausea.

Time frame:
Baseline to Week 8
Reported as:
Mean · score on a scale
Change in the Nausea Visual Analog Scale (NVAS)
score on a scaleOverall
Change in the Nausea Visual Analog Scale (NVAS)3.13 ± 29.089
Other pre-specifiedNumber of Participants With Patient Global Impression of Change (PGIc) Values

The PGIc is a 7-point Likert-type rating based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). PGIc values were measured at the ET or E/D, as applicable.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants With Patient Global Impression of Change (PGIc) Values
ParticipantsOverall
Very Much Improved1
Much Improved9
Minimally Improved12
No Change26
Minimally Worse3
Much Worse0
Very Much Worse0
Other pre-specifiedChange in Epworth Sleepiness Scale (ESS)

The ESS questionnaire included a set of 8 questions regarding how likely the participant would be to doze off or fall asleep in different situations. The ESS measures EDS or average sleep propensity in daily life. Responses range from 0 = would never doze (better outcome) to 3 = high chance of dozing (worse outcome). Changes in ESS scores were assessed between the Baseline period and ET or E/D, as applicable

Time frame:
Baseline to Week 8
Reported as:
Mean · units on a scale
Change in Epworth Sleepiness Scale (ESS)
units on a scaleOverall
Change in Epworth Sleepiness Scale (ESS)-0.6 ± 2.33
Other pre-specifiedTime to Achieve Optimized Dose and Regimen

Defined as the time from the first dose and regimen to the optimized dose and regimen of XYWAV, where the optimized dose and regimen indicates the final dose and regimen that remains unchanged throughout the remainder of the Intervention period.

Time frame:
Baseline to Week 8
Reported as:
Mean · day
Time to Achieve Optimized Dose and Regimen
dayOverall
Time to Achieve Optimized Dose and Regimen2.6 ± 4.90
Other pre-specifiedNumber of Changes From the First Dose and Regimen to Optimized Dose and Regimen

The amount of times the dose and regimen were changed before an optimized dose and regimen were achieved.

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
Number of Changes From the First Dose and Regimen to Optimized Dose and Regimen
ParticipantsOverall
Never Changed48
Changed Once6
Changed Twice0
Changed More than Twice0
Other pre-specifiedNumber of Participants Dosing Fasted Versus Dosing Without Consideration of Food

Once the participant reached an optimized dose and regimen, the investigator could decide to instruct the participant to dose without regard to food.

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
Number of Participants Dosing Fasted Versus Dosing Without Consideration of Food
ParticipantsOverall
Dosing Fasted53
Dosing without Food Consideration1
Other pre-specifiedDuration of Time Between the Last Meal Relative to Dosing

The difference between the time of day that participants ate their last meal and the time of day participants take their first dose.

Time frame:
Baseline to Week 8
Reported as:
Mean · minute
Duration of Time Between the Last Meal Relative to Dosing
minuteOverall
Duration of Time Between the Last Meal Relative to Dosing113.7 ± 313.31
Other pre-specifiedCharacterization of Meals Relative to Dosing

Types of meals consumed before dosing.

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
Characterization of Meals Relative to Dosing
ParticipantsOverall
Regular Meal54
Snack45
Beverage Other than Water19

Adverse events

Collected over Treatment-emergent adverse event (TEAE) data were collected from up to 30 days before Day 1 up to week 10 + 3 days.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall0/60 (0%)2/60 (3.3%)18/60 (30%)
Most frequent serious events
Most frequent serious events
EventOverall
HyperkalaemiaMetabolism and nutrition disorders1/60
FallInjury, poisoning and procedural complications1/60
Most frequent other events
Showing 10 of 25
Most frequent other events
EventOverall
DiarrhoeaGastrointestinal disorders2/60
NauseaGastrointestinal disorders2/60
COVID-19Infections and infestations2/60
NasopharyngitisInfections and infestations2/60
HeadacheNervous system disorders2/60
Night sweatsSkin and subcutaneous tissue disorders2/60
HaemorrhoidsGastrointestinal disorders1/60
ChillsGeneral disorders1/60
Oedema peripheralGeneral disorders1/60
ConjunctivitisInfections and infestations1/60

Baseline characteristics

Baseline characteristics were assessed using the Safety Analysis Set, which included all participants in the Enrolled Analysis set who received at least 1 dose of Xyrem after providing informed consent.

Age, Continuous
Age, Continuous(years)Overall
Mean44.3 ± 15.22
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female37
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino4
Not Hispanic or Latino58
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American6
White54
More than one race0
Unknown or Not Reported0
08

Study locations

28 sites
  • Wright Clinical Research, LLC
    Alabaster, Alabama 35007, United States
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Pulmonary Associates of the Southeast, PC
    Birmingham, Alabama 35254, United States
  • Santa Monica Clinical Trials
    Los Angeles, California 90025, United States
  • Southern California Institute For Respiratory Diseases, Inc./ Tower Sleep Medicine
    Los Angeles, California 90048, United States
  • Southern California Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Stanford University- Sleep Medicine
    Redwood City, California 94063, United States
  • SDS Clinical Trials, Inc
    Santa Ana, California 92705, United States
  • Delta Waves, Inc.
    Colorado Springs, Colorado 80918, United States
  • Pulmonary Disease Specialists, PA d/b/a PDS Research
    Kissimmee, Florida 34741, United States
  • Clinical Research of West Florida, Inc
    Tampa, Florida 33606, United States
  • Florida Pediatric Research Institute, LLC
    Winter Park, Florida 32789, United States
  • Sleep Practitioners LLC
    Macon, Georgia 31210, United States
  • Clinical Research Institute
    Stockbridge, Georgia 30281, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • WMed Center for Clinical Research
    Kalamazoo, Michigan 49008, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Clayton Sleep Institute, LLC
    Saint Louis, Missouri 63123, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Intrepid Research LLC
    Cincinnati, Ohio 45245, United States
  • Cleveland Clinic, Sleep Disorders Center
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences
    North Charleston, South Carolina 29425, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Nov 2022, 19 months.

Results were first posted in Jan 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 12, 2021
StartActual
Mar 22, 2021
Primary completionActual
Nov 15, 2022
CompletionActual
Nov 15, 2022
Results first posted
Jan 9, 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04794491
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Mar 22, 2021
Primary completion
Nov 15, 2022
Completion
Nov 15, 2022
Results posted
Jan 9, 2024
Last update
Jan 9, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JZP258

Start the discussion